Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC decreased its stake in Structure Therapeutics Inc. (NASDAQ:GPCR) by 3.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 232,909 shares of the company’s stock after selling 8,183 shares during the quarter. ArrowMark Colorado Holdings LLC’s holdings in Structure Therapeutics were worth $6,316,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. ANTIPODES PARTNERS Ltd boosted its holdings in Structure Therapeutics by 115.0% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after buying an additional 553 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Structure Therapeutics by 4,155.6% in the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after acquiring an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of Structure Therapeutics during the fourth quarter worth approximately $40,000. Virtus ETF Advisers LLC raised its stake in Structure Therapeutics by 25.5% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,242 shares of the company’s stock valued at $61,000 after purchasing an additional 455 shares during the last quarter. Finally, Assetmark Inc. lifted its holdings in Structure Therapeutics by 72.3% in the 4th quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock valued at $62,000 after purchasing an additional 953 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Stock Performance

GPCR stock opened at $27.09 on Friday. Structure Therapeutics Inc. has a one year low of $13.22 and a one year high of $62.74. The firm has a market cap of $1.55 billion, a PE ratio of -36.61 and a beta of -1.35. The firm’s 50 day moving average price is $20.52 and its 200-day moving average price is $27.38.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, February 27th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Equities research analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on GPCR. Citigroup assumed coverage on shares of Structure Therapeutics in a research report on Friday. They issued a “buy” rating and a $60.00 target price for the company. William Blair began coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. HC Wainwright restated a “buy” rating and issued a $80.00 price target on shares of Structure Therapeutics in a research report on Tuesday, April 22nd. Finally, Stifel Nicolaus started coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 price target for the company. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $78.63.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.